Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 11/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24792596 | 0.82 | MRGPRX4 (0.47) | MRGPRX4GPR119USP2HPGDTSHR | |
| SCHEMBL24791791 | 0.81 | GPR119 (0.47) | MRGPRX4GPR119 | |
| SCHEMBL24793335 | 0.80 | PDK4 (0.45) | GPR119PDK4 | |
| SCHEMBL24791820 | 0.79 | GPR119 (0.44) | MRGPRX4GPR119PDK4 | |
| SCHEMBL27168908 | 0.78 | MRGPRX4 (0.48) | MRGPRX4 | |
| SCHEMBL24793341 | 0.78 | MRGPRX4 (0.48) | MRGPRX4 | |
| SCHEMBL24791823 | 0.77 | GPR119 (0.48) | MRGPRX4GPR119 | |
| SCHEMBL30053719 | 0.77 | GPR119 (0.48) | MRGPRX4GPR119 | |
| SCHEMBL29826265 | 0.76 | CACNB4 (0.49) | MRGPRX4GPR119 | |
| SCHEMBL30745352 | 0.76 | MRGPRX4 (0.48) | MRGPRX4GPR119DPP4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4461355-A2 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | MRGPRX4 131/4885GPR119 4/4885DPP4 12/4885 |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | MRGPRX4 131/4885GPR119 4/4885DPP4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.